Vaccitech, a clinical-stage T cell immunotherapy company developing products to treat and prevent cancer and infectious diseases (ID), announced today that it has appointed Bill Enright as its new Chief Executive Officer (CEO). Mr. Enright succeeds Tom Evans, MD who will make a planned transition to the role of Vaccitech’s Chief Scientific Officer.
{iframe}https://www.b3cnewswire.com/201908271964/vaccitech-appoints-bill-enright-as-new-chief-executive-officer.html{/iframe}